Sean M. Smith

发表

Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.

John D. Schreier, I. Raheem, J. Fuerst, 2016, Bioorganic & medicinal chemistry letters.

Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis.

G. McGaughey, W. Shipe, J. Uslaner, 2015, Journal of medicinal chemistry.

Discovery, Optimization, and Biological Characterization of 2,3,6‐Trisubstituted Pyridine‐Containing M4 Positive Allosteric Modulators

Scott T. Harrison, J. Uslaner, Sean M. Smith, 2019, ChemMedChem.

Antinociceptive effects of potent, selective and brain penetrant muscarinic M4 positive allosteric modulators in rodent pain models

D. Henze, H. Meziane, Sean M. Smith, 2020, Brain Research.

T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats

Jason M. Uslaner, John J. Renger, Victor N. Uebele, 2012, Neuropharmacology.

Validation of a multiplexed and targeted lipidomics assay for accurate quantification of lipidomes

Daniel S Spellman, Monika Kandebo, Sean M. Smith, 2022, Journal of lipid research.

Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates.

Scott T. Harrison, K. K. Nanda, Monika Kandebo, 2012, ACS chemical neuroscience.

A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy

Dawn M. Toolan, Monika Kandebo, Sean M. Smith, 2021, Neurobiology of Disease.

LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson’s disease

Sean M. Smith, Lihang Yao, N. Hatcher, 2019, Neurobiology of Disease.

The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors

J. Uslaner, Sean M. Smith, P. Hutson, 2010, The open medicinal chemistry journal.

Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions

Monika Kandebo, Sean M. Smith, Lihang Yao, 2022, The Journal of Neuroscience.

Genetic Deletion and Pharmacological Inhibition of PDE10A Protects Mice from Diet-Induced Obesity and Insulin Resistance

Dawn M. Toolan, J. Renger, Sean M. Smith, 2013 .

Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity

Steven V. Fox, J. Uslaner, Sean M. Smith, 2016, Psychopharmacology.

Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.

John D. Schreier, I. Raheem, J. Fuerst, 2012, Bioorganic & medicinal chemistry letters.

Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species.

Dawn M. Toolan, G. McGaughey, J. Uslaner, 2018, Bioorganic & medicinal chemistry letters.

Combined administration of an mGlu2/3 receptor agonist and a 5-HT2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants

Sarah L. Huszar, J. Uslaner, Sean M. Smith, 2009, Psychopharmacology.

Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction

Dawn M. Toolan, Sean M. Smith, Jacob N. Marcus, 2021, Neurobiology of Aging.

Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease

Dawn M. Toolan, M. Nalls, A. Singleton, 2019, Human molecular genetics.

Genetic Deletion and Pharmacological Inhibition of Phosphodiesterase 10A Protects Mice From Diet-Induced Obesity and Insulin Resistance

Dawn M. Toolan, I. Raheem, J. Renger, 2013, Diabetes.

MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy

Lynn A. Hyde, E. Hostetler, J. Uslaner, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy

J. Uslaner, Sean M. Smith, J. Hess, 2018, PloS one.

Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A Inhibitor.

J. Uslaner, Sean M. Smith, S. Stachel, 2018, ACS medicinal chemistry letters.

Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors.

I. Raheem, L. Gantert, E. Hostetler, 2015, Bioorganic & medicinal chemistry letters.

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey

Dawn M. Toolan, John D. Schreier, I. Raheem, 2013, Neuropharmacology.

The Behavioral and Neurochemical Effects of a Novel d-Amino Acid Oxidase Inhibitor Compound 8 [4H-Thieno [3,2-b]pyrrole-5-carboxylic Acid] and d-Serine

Sarah L. Huszar, Monika Kandebo, J. Uslaner, 2008, Journal of Pharmacology and Experimental Therapeutics.

Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia

I. Raheem, J. Fuerst, Sarah L. Huszar, 2023, Journal of medicinal chemistry.

The identification of a novel lead class for phosphodiesterase 2 inhibition by fragment-based drug design.

Deping Wang, Sujata Sharma, W. Shipe, 2017, Bioorganic & medicinal chemistry letters.

Preclinical Characterization of the Phosphodiesterase 10A PET Tracer [11C]MK-8193

I. Raheem, L. Gantert, E. Hostetler, 2016, Molecular Imaging and Biology.

The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents

Dawn M. Toolan, Monika Kandebo, J. Uslaner, 2015, Neuropharmacology.

The dual orexin receptor antagonist, DORA‐22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine

Steven V. Fox, J. Uslaner, J. Renger, 2017, Journal of neurochemistry.

Regulation of dopamine signaling in the striatum by phosphodiesterase inhibitors: novel therapeutics to treat neurological and psychiatric disorders.

Sean M. Smith, Andres D. Ramirez, 2015, Central nervous system agents in medicinal chemistry.

Magnetic resonance imaging detects white adipose tissue beiging in mice following PDE10A inhibitor treatment

Sean M. Smith, T. Mcdonald, M. Tomaszewski, 2023, Journal of lipid research.

The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents

Lynn A. Hyde, J. Uslaner, Sean M. Smith, 2011, Neuropharmacology.

PHARMACOKINETICS AND PHARMACODYNAMICS TO SUPPORT CLINICAL STUDIES OF MK-8719: AN O-GLCNACASE INHIBITOR FOR PROGRESSIVE SUPRANUCLEAR PALSY

Dawn M. Toolan, Joseph James Duffy, Sean M. Smith, 2016, Alzheimer's & Dementia.

Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.

John D. Schreier, I. Raheem, J. Fuerst, 2012, Bioorganic & medicinal chemistry letters.

Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity

Steven V. Fox, J. Uslaner, Sean M. Smith, 2016, Psychopharmacology.

EARLY CLINICAL RESULTS AND PRECLINICAL VALIDATION OF THE O-GLCNACASE (OGA) INHIBITOR MK-8719 AS A NOVEL THERAPEUTIC FOR THE TREATMENT OF TAUOPATHIES

Dawn M. Toolan, Joseph James Duffy, J. Renger, 2016, Alzheimer's & Dementia.

Synthesis and optimization of N-heterocyclic pyridinones as catechol-O-methyltransferase (COMT) inhibitors.

Scott T. Harrison, Monika Kandebo, Sean M. Smith, 2016, Bioorganic & medicinal chemistry letters.